Novo Nordisk A/S (NYSE:NVO) Position Trimmed by Norden Group LLC

Norden Group LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.5% during the fourth quarter, Holdings Channel reports. The firm owned 25,777 shares of the company’s stock after selling 3,681 shares during the quarter. Novo Nordisk A/S comprises 0.4% of Norden Group LLC’s portfolio, making the stock its 19th largest holding. Norden Group LLC’s holdings in Novo Nordisk A/S were worth $2,667,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of NVO. Clarius Group LLC lifted its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after purchasing an additional 93 shares in the last quarter. Tradewinds Capital Management LLC raised its position in Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after buying an additional 95 shares during the period. Relyea Zuckerberg Hanson LLC lifted its stake in Novo Nordisk A/S by 3.2% in the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after acquiring an additional 99 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its stake in Novo Nordisk A/S by 3.5% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after acquiring an additional 100 shares in the last quarter. Finally, Highlander Capital Management LLC boosted its position in Novo Nordisk A/S by 0.4% during the 4th quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after acquiring an additional 100 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on NVO. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Up 1.3 %

NYSE NVO traded up $1.64 during trading on Tuesday, reaching $128.52. The company’s stock had a trading volume of 5,897,834 shares, compared to its average volume of 4,776,079. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $576.74 billion, a PE ratio of 47.77, a PEG ratio of 2.12 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The business has a 50-day moving average price of $126.92 and a 200-day moving average price of $112.40.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.